The European Medicines Agency is looking to sublet its former headquarters in the financial district of London, after a British court ruled on Wednesday (20 February) that it cannot break its lease despite the UK’s withdrawal from the EU.
More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foste...
Brexit poses “serious challenges” to the NHS in the form of longer waiting times, staff shortages and delays in the approval of new medicines, according to a report published on Wednesday (14 March).
The smooth transition of the EU drug agency from London to Amsterdam is threatened by delays in the Netherlands, whose bid to win the agency may have been misleading, a top representative of Italian pharmaceuticals told EURACTIV.com.
Dutch officials and the head of the European Medicines Agency (EMA) sought yesterday (29 January) to allay any jitters among the agency's 900 London-based staff who are being asked to move to Amsterdam because of Britain's departure from the EU.
Public health organisations and EU lawmakers say the closed-door meetings before the submission of a new drug between the pharma industry and the European Medicines Agency (EMA), a key player in the continent’s healthcare industry, should be more transparent.
LONDON: Patients in Britain risk delays to access life-saving medicines if the UK deviates from EU regulatory standards post-Brexit, a leading medical representative has warned.
At the end of a suspenseful day, delegates from 27 EU governments meeting in the General Affairs Council chose to relocate the European Medicines Agency to Amsterdam and the European Banking Authority to Paris. EURACTIV France reports.